Xenon Pharmaceuticals (XENE)

P/S ratio as of February 2026 (TTM): 416

According to Xenon Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.58. At the end of 2025 the company had a P/S ratio of 390.

P/S ratio history for Xenon Pharmaceuticals from 2014 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	390
2024	N/A
2023	N/A	-100%
2022	261	199.04%
2021	87.4	422.16%
2020	16.7	-69.01%
2019	54.0
2018	N/A	-100%
2017	163	113.95%
2016	76.4	929.18%
2015	7.42	-24.79%
2014	9.87

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Coherus BioSciences CHRS	3.02	-99.27%	🇺🇸 USA
Atara Biotherapeutics ATRA	0.2140	-99.95%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Xenon Pharmaceuticals (XENE)

P/S ratio as of February 2026 (TTM): 416